All Articles

A new ETF, EXEQ, uses AI to score and invest in corporate leadership, aiming to turn a qualitative trait into a data-driven source of returns.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

Meltwater is now an Official Reddit Data Partner, unlocking a goldmine of unfiltered consumer insights. What does this mean for brands and data privacy?

A new report reveals America's youngest workers face a crisis of confidence while the much-hyped AI revolution stalls in the workplace.

Titanium Transportation offers shareholders a 41% premium to go private, a strategic retreat from public markets amid a punishing freight recession.

Couples are now using Valentine's Day to plan luxury destination weddings, with immersive pre-wedding trips to places like Switzerland gaining popularity.

Paris reaffirms support for the Africa Adaptation Acceleration Program, a move signaling deeper diplomatic ties and a focus on African-led solutions.

Las Vegas Sands names Patrick Dumont CEO, signaling a new chapter focused on executing massive multi-billion dollar investments in Macao and Singapore.

A new online pharmacy is challenging the 'prescribe and forget' model for weight loss drugs, offering integrated clinical care to combat safety concerns.

Jasmine Hartin is vindicated as drug and assault charges are dismissed, raising questions about a 'weaponized' legal system in her ongoing public saga.

A U.S. firm enters Puerto Rico's embattled water market, promising advanced filtration for hospitals and hotels plagued by infrastructure woes.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

With 15 'Best Bank' awards fueled by client feedback and record SBA lending, Huntington Bank demonstrates a winning formula for business banking success.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

Formula 1 phenom Ollie Bearman isn't just endorsing IM8 Health; he's investing in it, signaling a major shift in how athletes partner with brands.

A $1.1 billion joint venture in Kazakhstan is set to develop the world's largest tungsten reserve, challenging China's dominance in a critical mineral.

Veradigm's new platform aims to merge patient stories with clinical data, but faces a competitive market and lingering questions about data privacy.

A new software upgrade uses AI to make low-cost drones perform like high-end systems, a breakthrough with major implications for defense and industry.

The Canadian restaurant giant defied a tough market in 2025, posting record sales and boosting investor payouts through strategic promotions and delivery.